1.402 articles found

Progression of Dopaminergic Therapy Changes in Parkinson's Disease in Asian and Native Hawaiian and Pacific Islander Populations.

Borrello K, Nakahira S, Fontana P, Guittu D, Hunter C, Lee A, Jahansooz J, Weldon E, Roman M, Ahn HJ, Carrazana E, Liow K.

Mov Disord Clin Pract · 2024-11-18

DOI: 10.1002/mdc3.14280PMID: 39555887

Missing appointments in Parkinson´s Disease: A longitudinal study on the pattern of attendance and its effects on motor and non-motor symptoms, quality of life and disability progression.

Magriço M, Meira B, Fernandes M, Salavisa M, Marto JP, Barbosa R, Bugalho P.

Clin Neurol Neurosurg · 2024-11-12

DOI: 10.1016/j.clineuro.2024.108641PMID: 39549367

Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study.

Song T, Zhou X, Wang C, Wu H, Yan X, Guo J, Tang B, Lei L, Xu Q, Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD‐MDCNC).

Ann Clin Transl Neurol · 2024-11-11

DOI: 10.1002/acn3.52244PMID: 39529459

The association of motor reserve and clinical progression in Parkinson's disease.

Bai X, Zhang S, Li Q, Guo T, Guan X, Qian A, Chen S, Zhou R, Cheng Y, Chen H, Gou Z, Xie C, Wang Z, Zhang M, Zheng X, Wang M.

Neuroimage Clin · 2024-11-09

DOI: 10.1016/j.nicl.2024.103704PMID: 39536522

The Impact of the Blood-Brain Barrier and Its Dysfunction in Parkinson's Disease: Contributions to Pathogenesis and Progression.

Khalid Iqbal M, Khan B, Hifsa, YuXuan G, Mujahid M, Kiyani MM, Khan H, Bashir S.

ACS Omega · 2024-11-05

DOI: 10.1021/acsomega.4c06546PMID: 39583664

Hsa_Circ_0105596/FTO inhibits progression of Parkinson's disease by sponging miR-187-3p and regulating eEF2.

Feng J, Zhao J, Kuang Y, Zhou Y, Ye Z, He Y, Chen D, Zhang L, Zhang T, Zhu Q, Cheng S, Liu T.

Heliyon · 2024-11-02

DOI: 10.1016/j.heliyon.2024.e39830PMID: 39654770

Clinical progression of Parkinson's disease in the early 21st century: Insights from the accelerating medicine partnership (AMP-PD) data.

Lewis MM, Mailman RB, Cheng XV, Du G, Zhang L, Li C, De Jesus S, Tabbal SD, Li R, Huang X.

Parkinsonism Relat Disord · 2024-11-02

DOI: 10.1016/j.parkreldis.2024.107186PMID: 39541725

Unraveling the interplay of β-amyloid pathology and Parkinson's disease progression: Insights from autopsy-confirmed patients

Chen L, Lu H, Mao L, Lin J, Liu P.

Heliyon · 2024-11-01

Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease.

Bernal EA, Yang S, Herbst K, Venuto CS.

Clin Transl Sci · 2024-11-01

DOI: 10.1111/cts.70066PMID: 39513668

Impact of Dance or Music and Meditation on the Progression of Parkinson Disease With Mild or Moderate Severity: Protocol for a Pilot Randomized Controlled Trial.

Mehrotra B, Rai N, Mr R, Budhakar A, Aggarwal R, Agarbattiwala RV, Thomas M, Patole S, Doshi P.

JMIR Res Protoc · 2024-10-29

DOI: 10.2196/59018PMID: 39471378

Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [¹⁸F]FDG-PET study.

Orso B, Mattioli P, Yoon EJ, Kim YK, Kim H, Shin JH, Kim R, Famà F, Brugnolo A, Massa F, Chiaravalloti A, Fernandes M, Spanetta M, Placidi F, Pardini M, Bauckneht M, Morbelli S, Lee JY, Liguori C, Arnaldi D.

NPJ Parkinsons Dis · 2024-10-25

DOI: 10.1038/s41531-024-00813-zPMID: 39448609

Medication recommendation for Parkinson's disease based on dynamics of symptom progression.

Oh M, Kim H, Lee HK.

Sci Rep · 2024-10-23

DOI: 10.1038/s41598-024-76941-6PMID: 39443590